GlassScriptPhysician profile
Michael B Kusic
NPI 1154392900
$322.32
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.01 · 2021: $33.15 · 2022: $137 · 2023: $49.12 · 2024: $87.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.38 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $60.43 | 2022 | |
| Sumitomo Pharma America, INC. | $43.79 | 2023-2024 | Myfembree |
| Aspira Women'S Health INC | $41.43 | 2022-2023 | Ova1 |
| Exact Sciences Corporation | $34.98 | 2024 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $33.15 | 2021 | |
| Organon LLC | $26.68 | 2024 | |
| Mayne Pharma Commercial LLC | $21.91 | 2022 | |
| Avion Pharmaceuticals | $19.23 | 2022 | |
| Merck Sharp & Dohme LLC | $15.01 | 2019 | |
| Millicent US INC | $13.35 | 2023 | Femring |
| Smith+Nephew, INC. | $12.36 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kusic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.